A change in the metformin label was once more clearly needed. However, because metformin is a generic drug, it lacked a pharmaceutical industry sponsor to take up its cause. Hence, in 2012 and 2013, we filed 2 separate citizen petitions to the FDA, one from collaborators at Cornell and the University of Pennsylvania and one from Yale (cosigned by 111 diabetes experts), asking the FDA to change the label and to relax the renal contraindications.
In April of 2016, the FDA issued a safety communication that partially granted our requests by requiring the manufacturers of metformin to change the labeling of metformin in several ways (Table) . Metformin is still contraindicated in patients with severe kidney dysfunction, defined as an estimated glomerular filtration rate (eGFR) <30 mL·min −1 ·1.73 m −2 . However, its use is now allowed in patients with mild to moderate kidney dysfunction, defined as an eGFR between 30 and 60 mL·min . These changes could increase the estimated number of US patients with type 2 diabetes mellitus who are eligible to take metformin by ≈900 000 to 2.5 million.
In addition, the FDA changed the requirements for discontinuation of metformin around administration of iodinated contrast media. Previously, the metformin label recommended that the drug be temporarily discontinued at the time of or before any radiological procedure with intravascular contrast, withheld for 48 hours after the procedure, and restarted only after renal function was found to be normal. This warning, however, did not make a distinction between patients with various degrees of kidney dysfunction. The new label recommends stopping metformin at the time of or before administration of iodinated intravenous contrast only in patients with an eGFR <60 mL·min −1 ·1.73 m −2 or in patients with a history of liver disease, alcoholism, or heart failure. eGFR should then be re-evaluated after 48 hours, with metformin restarted if kidney function is stable. These recommendations are based on the minimal risk of metformin-associated lactic acidosis in patients without chronic kidney disease undergoing intravenous iodinated contrast media administration.
Of note, the FDA now makes a distinction between intravenous and intra-arterial contrast administration, recommending that metformin be held, regardless of eGFR, when intra-arterial contrast is given such as during cardiac catheterization. There are few data to back this specific recommendation, and the agency does not elaborate on distinct vascular territories and their proximity to the renal arterial supply or the volume of con- THE PULSE trast used. The American College of Radiology agrees that in patients undergoing "arterial catheter studies that might result in emboli (atheromatous or other) to the renal arteries," metformin should be temporarily discontinued at the time of or before the procedure and restarted 48 hours after the procedure only after kidney function is found to be normal. 4 The rationale appears to be that certain intra-arterial procedures confer a higher risk for contrast-induced nephropathy resulting from atheroembolic sequelae, as well as, perhaps, a more abrupt and concentrated dose of contrast delivered to the kidneys.
Because data on the benefits and harms of medications evolve over time, the FDA must continually revisit the questions of effectiveness and safety for existing drugs as new evidence emerges. Clinicians and researchers can influence this process by formally petitioning the agency. The case of metformin suggests that this mechanism can be effective.
What is involved in filing a citizen petition? A petition must include a description of actions being requested, and these actions must fall under the jurisdiction of the FDA commissioner. Moreover, the petition must include a persuasive statement of grounds such as data from randomized, controlled trials. Finally, it must include a statement on environmental and economic impacts (if any), as well as certification that the evidence included is well balanced and unbiased. The citizen petition needs to be submitted electronically.
Despite the availability of this mechanism to affect drug policy, citizen petitions are infrequently filed by clinicians. Of 1915 citizen petitions filed between 2001 and 2013, 82% were filed by individuals working for industry. 5 Most of these petitions were focused primarily on blocking or delaying FDA approval of generic products to extend brand market profitability. When citizen petitions are filed by individuals or organizations not working on behalf of industry, they most often request labeling changes, addition or removal of boxed warnings, risk communications, or placement of drugs into a Risk Evaluation and Mitigation Strategy. On average, it takes the FDA 3 years to reach a final decision, and it denies the petitioners' request in the vast majority of cases (87%). 5 Why were the metformin petitions successful? The initial decision to restrict the use of metformin in patients with kidney dysfunction was based partly on experience with an earlier drug in the same biguanide class, phenformin. However, phenformin was associated with a much higher risk of lactic acidosis compared with metformin. Multiple studies have since evaluated the risk of lactic acidosis in metformin-treated patients and found it to be exceedingly low. 2 In addition, the initial label for metformin was based on serum creatinine cut points before the ubiquitous use of eGFR in clinical practice. Given these considerations and the long-standing safety record of metformin, we were able to make a strong case that the benefits of metformin outweigh the potential risk in patients with mild to moderate kidney disease.
What are the implications for cardiologists? Until recently, metformin was the only glucose-lowering agent shown to improve cardiovascular outcomes. Emerging evidence now suggests that members of 3 other diabetes drug classes (sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 agonists, and thiazolidinediones) reduce cardiovascular events in those with established macrovascular disease. The decision to use one class of agents over another will depend on other considerations, including distance from the hemoglobin A 1c target, side effects and safety considerations, patient preferences, and, importantly, cost. With the new label changes, metformin remains an excellent option in stable patients with mild to moderate chronic kidney disease, and its use in patients undergoing contrast procedures has become much simpler. 
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